Core Viewpoint - Chengdu is actively promoting technological innovation and transformation within its industrial parks through the "Optimize Quality, Characteristic Park, Empower Efficiency, Full Park" initiative, aiming to enhance innovation capabilities and drive high-quality development [4][5]. Group 1: Technological Innovation Promotion - Chengdu plans to implement the "Optimize Quality, Characteristic Park, Empower Efficiency, Full Park" action in all national, provincial, and municipal development zones starting in October 2024 [4]. - The city aims to enhance the innovation source capability, transformation承接力, and resource allocation in its industrial parks, thereby injecting new momentum into technological innovation [4][5]. - Chengdu has established a high-energy innovation system, including 1 national laboratory, 4 national innovation centers, 10 large scientific devices, and 4 Tianfu laboratories [4]. Group 2: Achievements in Technological Innovation - Significant breakthroughs have been achieved, such as the "China Circulation No. 3" artificial sun reaching over 100 million degrees Celsius and the world's first gallium nitride quantum light source chip being developed [4]. - The city has successfully approved several key projects, including the Taixing Laboratory's experimental device and the establishment of the Sichuan Provincial Crystalline Silicon Photovoltaic Technology Innovation Center [4][5]. Group 3: Technology Transfer and Collaboration - Chengdu has organized nearly 300 technology transfer events this year, facilitating over 400 industry-academia-research cooperation projects [5]. - The "Science and Technology Innovation Tianfu · Wisdom Gathering Rongcheng" event has brought together over 70 representatives from research institutions, technology transfer teams, and enterprises to promote technology and industry alignment [5]. Group 4: Resource Allocation and Ecosystem Development - Chengdu is focusing on enhancing the operational capacity of innovation resources within its industrial parks, including the establishment of shared laboratories and mid-test platforms [5]. - The city has seen the establishment of 141 mid-test platforms and concept verification centers, supporting various key industry chains [5]. - Chengdu's technology finance service system has been optimized, providing credit loans of 8.443 billion yuan to 1,709 technology enterprises from January to September this year [5].

Industry Rating - The report rates the pharmaceutical industry as "Leading" [1] Core Insights - The report emphasizes the significance of the ESMO conference, highlighting the achievements of Chinese pharmaceutical companies and suggesting to focus on catalysts such as policies, academic conferences, and business development in Q4 2025 [1][4] - The report indicates a potential market rebound due to increasing industry catalysts, including various academic conferences and favorable policies [4] - The report recommends continued attention to companies with promising clinical pipelines and their global commercialization potential [4][5] Valuation Summary - The report provides a detailed valuation overview of various companies, with all covered companies rated as "Buy" except for two rated as "Neutral" and one as "Sell" [3] - Notable target prices and current prices for selected companies include: - AstraZeneca: Target price 93.30, Current price 83.87 [3] - BeiGene: Target price 225.00, Current price 188.20 [3] - Innovent Biologics: Target price 48.00, Current price 36.42 [3] - I-Mab: Target price 105.00, Current price 86.10 [3] - China Biologic Products: Target price 9.10, Current price 7.43 [3] Market Performance - The Hang Seng Index rose by 2.3% and the Hang Seng Healthcare Index increased by 2.0% during the week of October 14-21, 2025, ranking fifth among twelve industry indices [4][7] - Sub-industry performance showed CXO leading with a 4.5% increase, followed by Internet medicine and biopharmaceuticals [4][7] Institutional Holdings - As of October 21, 2025, the proportion of domestic institutional holdings through Hong Kong Stock Connect decreased slightly to 22.1%, while foreign institutional holdings also saw a minor decline to 38.6% [34][38] - The report notes that both domestic and foreign investors are increasing their positions in innovative drug companies with clear pipeline values [4][38] Clinical Developments - The report highlights significant clinical trial results presented at the ESMO conference, including: - CanSino Biologics' promising data on its PD-1/VEGF inhibitor [5][6] - Rongchang Biopharmaceuticals' HER2 ADC showing significant survival benefits [5][6] - Kelun-Biotech's results indicating substantial improvements in progression-free survival [5][6] - The report suggests that these developments enhance the global competitiveness of the covered companies [5][6]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2][47]. Core Insights - The report highlights that the medical device procurement is gradually reflecting principles of "stabilizing clinical needs, ensuring quality, preventing collusion, and countering price wars" [6][30]. - The report suggests that the recent adjustments in procurement rules indicate a shift towards a more moderate approach, focusing on clinical needs and product quality rather than solely on low prices [6][30]. - The report emphasizes the potential for long-term development in the domestic medical device industry as procurement becomes more reasonable [6][30]. Summary by Sections Industry Overview - The closing index for the medical and biological sector is 8583.87, with a 52-week high of 9323.49 and a low of 6764.34 [2]. Market Performance - During the week of October 13-17, 2025, the A-share medical and biological sector fell by 2.48%, underperforming the CSI 300 index by 0.26 percentage points but outperforming the ChiNext index by 3.23 percentage points [7][36]. - The Hang Seng Healthcare Index decreased by 5.85%, underperforming the Hang Seng Index by 1.88 percentage points [7][36]. Industry Opinions and Investment Recommendations 1. **Innovative Drugs**: The innovative drug sector is experiencing adjustments, with a recommendation to maintain or increase positions based on long-term industry development logic. Key companies to watch include Innovent Biologics, 3SBio, and others [8][21]. 2. **Medical Devices**: The report notes that the National Medical Insurance Administration's recent procurement documents aim to optimize price differences and control "anchor points," indicating a move away from simply selecting the lowest bid [8][29]. 3. **Research Services**: The report expresses optimism about investment opportunities in the research services sector, particularly for companies with strong competitive advantages [26]. Sector Valuation - As of October 17, 2025, the overall valuation of the medical sector (TTM) is 30.03, a decrease of 0.84 from the previous week. The sector's valuation premium over the CSI 300 index is 123.96%, down by 4.90 percentage points [43].

Investment Rating - The report maintains an investment rating of "Outperform" for the biopharmaceutical sector [8]. Core Insights - The report highlights several catalysts for the sector, including academic conferences, business development (BD) achievements, medical insurance negotiations, and innovative drug directories from commercial insurance [21]. - Key companies to watch include: 1. Products with high certainty for overseas expansion certified by MNCs: PD-1 upgraded products from Sanofi and GLP-1 assets from Federal Pharmaceuticals [21]. 2. Potential blockbuster products for overseas licensing from MNCs: PD-1 upgraded products from Kangfang Biotech and Innovent Biologics, breakthroughs in autoimmune fields from Yifang Biotech and China Antibody, and innovative target ADCs from Fuhong Hanlin and Shiyao Group [21]. 3. Companies likely to benefit from medical insurance negotiations and innovative drug directories: Heng Rui Medicine, Kangnuo Pharmaceutical, Maiwei Biotech, Zhixiang Jintai, and Haichuang Pharmaceutical [21]. Summary by Sections Weekly New Drug Market Review - From October 13 to October 19, 2025, the top five gainers in the new drug sector were: - Sanofi National Health (+12.68%) - Kangning Jereh (+10.18%) - Rongchang Biotech (+5.42%) - Xiansheng Pharmaceuticals (+4.88%) - Qianyan Biotech (+3.77%) - The top five losers were: - Yongtai Biotech (-29.76%) - Betta Pharmaceuticals (-16.98%) - Yiming Oncology (-16.80%) - Deqi Pharmaceuticals (-15.30%) - WuXi Biologics (-13.43%) [4][16]. New Drug Industry Focus Analysis - Recently, Bai Li Tianheng presented overseas multi-center solid tumor research data for its EGFR×HER3 dual antibody ADC drug, iza-bren, at the 2025 European Society for Medical Oncology (ESMO) annual meeting. The data showed consistent efficacy and safety across different populations, confirming the broad-spectrum tumor-killing efficacy of iza-bren [21][24]. New Drug Approval and Acceptance - This week, one new drug or new indication application was approved, and 13 new drug or new indication applications were accepted in China [9][27]. - Additionally, 30 new drug clinical applications were approved, and 47 new drug clinical applications were accepted [10][30].

Investment Rating - The report indicates a strong performance in the biopharmaceutical innovation sector, particularly highlighting the significant growth in the Hong Kong innovation drug sector, which saw a cumulative increase of 59.51% in the first half of 2025, outperforming both A-shares and the Hang Seng Index [7]. Core Insights - The report emphasizes the impressive sales performance of Fitinib in China, with a notable increase in sales from 2019 to 2024, despite a temporary decline in the first half of 2025 due to intensified market competition and strategic adjustments [9][10]. - Fitinib has received multiple approvals in major markets, including the U.S., Europe, and Japan, with sales expected to continue growing due to expanding indications and deeper market penetration [17][18]. - The report highlights the clinical efficacy of Fitinib in treating metastatic colorectal cancer, demonstrating significant improvements in overall survival (OS) and progression-free survival (PFS) compared to other treatments [22][24]. Summary by Sections Market Dynamics - Fitinib's sales in China have shown an upward trend from 2019 to 2024, with a peak sales figure of 115 million USD in 2024, although the first half of 2025 saw a decline to 43 million USD, a 29% decrease year-on-year due to market competition and strategic changes [9][10]. - The report notes that the sales volume in hospitals increased from 13,000 boxes in 2021 to 24,100 boxes in 2024, indicating a growing market acceptance [9]. Competitive Landscape - The competitive landscape for Fitinib is characterized by aggressive bidding strategies, with the company actively participating in tenders across multiple provinces in China, leading to significant price reductions post-medical insurance negotiations [14][15]. - The report outlines the pricing dynamics, showing a substantial price drop of 68% in the first year after Fitinib was included in the medical insurance list, with ongoing negotiations further driving prices down [15]. Clinical Performance - Fitinib has shown superior clinical outcomes in treating metastatic colorectal cancer, with the FRESCO-2 trial reporting a median OS of 7.4 months compared to 4.8 months for the placebo group, and a median PFS of 3.7 months versus 1.8 months [22][24]. - The report also highlights the potential of Fitinib in treating gastric cancer, where it has demonstrated promising efficacy compared to other available treatments [26][29]. Pipeline and Future Prospects - Fitinib's pipeline includes various ongoing studies targeting multiple cancer indications, with several trials reaching significant endpoints or receiving regulatory approval, indicating a robust development trajectory [29]. - The report mentions a licensing agreement with Takeda for global commercialization outside of China, which includes an upfront payment of 400 million USD, showcasing the drug's potential in international markets [19].

Core Viewpoint - The article discusses the recent licensing agreement between Innovent Biologics and Zenas, highlighting market concerns regarding the low upfront payment and the financial stability of Zenas, a relatively new player in the biopharmaceutical industry [1][2]. Group 1: Transaction Overview - Innovent Biologics announced a licensing agreement with Zenas for the global exclusive rights to the BTK inhibitor, Oubatinib, with a potential total transaction value exceeding $2 billion [1]. - The upfront payment from Zenas consists of $35 million in cash, $65 million in milestone payments, and approximately $146 million worth of Zenas stock, with the remaining over $1.7 billion contingent on future milestones [2]. Group 2: Market Reaction - The market reacted negatively to the transaction, with Innovent's stock price dropping approximately 21.8% over two trading days following the announcement, primarily due to the low upfront payment, which constitutes only 1.75% of the total deal value [1][2]. - Concerns about Zenas's ability to fulfill its commitments arise from its status as a clinical-stage company with only $10 million in revenue and a net loss of approximately $8.58 million in the first half of 2025 [2]. Group 3: Product Background - Oubatinib is a key product for Innovent, being the first and only approved BTK inhibitor for the treatment of relapsed or refractory marginal zone lymphoma in China, with significant sales growth reported [3]. - The product has been previously licensed to Biogen, which later terminated the agreement, raising questions about the product's market viability and the reliability of future revenue from Zenas [3]. Group 4: Strategic Implications - Innovent's management emphasized the importance of business development (BD) as a priority for the next three years, indicating a strategic focus on international expansion [5]. - The company retains core rights to Oubatinib in oncology while licensing non-core rights, reflecting a strategy to balance risk and reward in its international ventures [5].

Core Viewpoint - The Hong Kong pharmaceutical sector has been experiencing a continuous decline, with significant drops in stock prices for several companies as of October 14. Group 1: Stock Performance - Vya Bio (01873.HK) has seen a decline of 7.53%, trading at 2.58 HKD [2] - Gilead Sciences-B (01672.HK) has dropped by 7.09%, with a current price of 9.17 HKD [2] - Connexa-B (02162.HK) has decreased by 5.74%, now priced at 64 HKD [2]

Group 1 - Pharmaceutical stocks have been experiencing a continuous decline, with notable drops in companies such as Viatris (01873) down 7.53% to HKD 2.58, and Singlomics (01672) down 7.09% to HKD 9.17 [1] - Huaxin Securities indicates that the trend of going global will continue into Q3 2025, but there are fewer significant business developments (BD) from listed companies, and NewCo-style BDs have not met market expectations [1] - The escalation of Sino-US trade conflicts may raise concerns about future decoupling risks, but the shift of global innovative R&D towards more efficient Chinese solutions is an unstoppable trend [1] Group 2 - Cinda Securities believes that Chinese innovative pharmaceutical companies are gaining global competitiveness in various niche markets, and while there may be short-term policy impacts, the long-term industry trend remains unchanged [2] - The innovative drug sector is expected to be a key focus in the next 2-3 years, despite potential short-term pullbacks [2] - The CXO sector is currently in a recovery phase, with continuous growth in performance expected to restore market confidence, and the recent iterations of the Biodefense Act have had minimal impact on leading companies [2]

Group 1 - The pharmaceutical stocks have been experiencing a continuous decline, with notable drops in companies such as Viatris (down 7.53% to HKD 2.58), Genscript Biotech (down 7.09% to HKD 9.17), and CanSino Biologics (down 5.74% to HKD 64) [1] - Huaxin Securities indicates that the trend of going global will continue into Q3 2025, but there are fewer significant business developments (BD) from listed companies, and the NewCo format of BD has not met market expectations [1] - The escalation of Sino-US trade conflicts may raise concerns about future decoupling risks, but the shift of global innovative research and development towards more efficient Chinese solutions is an unstoppable trend [1] Group 2 - Cinda Securities believes that Chinese innovative pharmaceutical companies are gaining a foothold on the global stage, possessing global competitiveness in various niche areas, despite potential short-term policy impacts [2] - The innovative drug sector is expected to remain a key focus for the next 2-3 years, with the CXO industry playing a crucial role in the global innovative drug supply chain [2] - The revised version of the Biodefense Act has undergone multiple iterations, with minimal impact on leading companies, and the CXO sector is currently experiencing a recovery phase, with continuous growth in performance likely to restore market confidence [2]

Core Insights - In the first three quarters of this year, 98% of the 976 comparable ordinary equity funds achieved positive performance, with only 23 funds experiencing declines [1] Group 1: Top Performing Funds - The top four performing ordinary equity funds, namely Huaan Pharmaceutical Biotechnology Stock A, Huaan Pharmaceutical Biotechnology Stock C, E Fund Information Industry Select Stock A, and E Fund Information Industry Select Stock C, all saw their performance double, with increases of 103.31%, 102.65%, 102.03%, and 101.26% respectively [1] - Huaan Pharmaceutical Biotechnology Stock's second-quarter report indicates heavy investments in companies such as Innovent Biologics, CSPC Pharmaceutical Group, and others, with significant stock price increases, particularly for 3SBio, which surged over four times [1] - E Fund Information Industry Select Stock's top ten holdings are primarily in the semiconductor sector, including companies like NewEase, Huitian Technology, and Tencent Holdings [1] Group 2: Fund Management and Performance - The E Fund Information Industry Select Stock is managed by Zheng Xi, who has extensive experience in equity investment management and has held various roles within E Fund [2] - Other notable funds such as E Fund Strategic Emerging Industries Stock A and C, and Jiashi Mutual Selection Stock A and C, also reported over 90% increases in the first three quarters [2] - Jiashi Mutual Selection Stock focuses on pharmaceutical stocks, with major holdings in companies like Innovent Biologics and Hengrui Medicine, managed by Hao Miao, who has a strong background in biomedical research [2] Group 3: Underperforming Funds - The fund with the largest decline, Minsheng Jianyin Preferred Stock, fell by 7.39%, primarily investing in blue-chip consumer stocks [4] - The fund's top ten holdings include companies like CATL and BYD, with the current manager, Liu Hao, having less than a year of experience [4] - Other underperforming funds include Changxin Consumer Select Quantitative Stock and Qianhai Kaiyuan Traditional Chinese Medicine Stock, both down by over 5% [4]